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a b s t r a c t
HIV/HCV co-infection provides a model to determine the role of immunity on HCV transmission and
evolution. In this study HCV transmission and evolution were evaluated in 6 HCV seroconverters in HIV-
infected subjects with a wide range of CD4 cell count. The HCV envelope E1/E2 sequences were analyzed
for transmission bottleneck, viral diversity/divergence, immune pressure, and mutations of HLA class I/II
restricted epitopes. HCV infection started with transmission bottleneck in all HIV-infected individuals.
During the 1.0–2.0 years of infection there was a shift of viral quasispecies in majority of the subjects
from one to next visit. However, HCV diversity, divergence, mutations in HLA class I/II restricted and virus
neutralizing epitopes were similar in all subjects regardless of CD4 cell count at the time of HCV
infection. Our results suggest that HCV transmission and evolution in HIV-infected subjects may not be
inﬂuenced by host CD4 cell count at the time of infection.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Hepatitis C virus (HCV) is a RNA virus that currently infects over
150 million people across the world. While a majority of infected
subjects become chronically infected, which leads to chronic hepatitis,
cirrhosis and hepatocellular carcinoma, approximately 25% of HCV-
infected individuals spontaneously clear HCV during the ﬁrst year of
infection (Micallef et al., 2006). Since human immunodeﬁciency virus
(HIV) and HCV share similar routes of transmission, such as exposure
to contaminated blood and sexual activity, approximately 25% of HIV-
infected persons are co-infected with HCV, which is much higher than
the HCV prevalence in the general world population (Ghosn et al.,
2006; Urbanus et al., 2009). HIV/HCV co-infection has been shown to
decrease the probability of spontaneous HCV clearance and increase
the rate of progression to cirrhosis, decompensated liver disease,
hepatocellular carcinoma, and death (Lewden et al., 2005; Weber
et al., 2006). Furthermore, HIV co-infection reduces efﬁcacy of drug
therapy against HCV (Rodriguez-Torres, 2012, 2013).
Because of lack of proofreading activity of viral RNA-
dependent DNA or RNA polymerases, HIV and HCV replication
results in a family of related genomic variants, or quasispecies.
Recent studies reveal that after HIV transmission, a single or a
few founder viruses are responsible for establishing productive
HIV infection in 80% of the sexually transmitted recipients and
40% of the recipients exposed to HIV contaminated blood, even
though a swarm of viral quasispecies is present in donor genital
ﬂuids and blood (Bar et al., 2010). Similar transmission bottleneck
has been reported for HCV infection (Bull et al., 2011; Li et al.,
2012). However, it is not clear whether the HCV transmission
bottleneck still exists in immunocompromised HIV/HCV co-
infected individuals. Moreover evolution dynamics of HIV and
HCV in co-infected individuals pose a great challenge for host
immunity to control these two viruses which could have impor-
tant implications for the HCV pathogenesis in HIV-infected
subjects. In HIV/HCV co-infected subjects, viral genome evolution
is determined by the rates of viral replication, genomic mutation,
and adaptive immune pressure to each of these two viruses.
Currently it is unclear how host immunity controls respective
viral replication in HIV/HCV co-infected subjects. The intricate
mutual effect may propel the HCV disease progression in HIV/
HCV co-infected subjects.
In this report we investigated transmission and evolution of
HCV in six HIV-infected individuals with a wide range of CD4 cell
count (13–807 cell/mm3) when HCV infection occurred.
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Results
The genetic transmission bottleneck of HCV infection
A total 19 plasma specimens from the six HCV early serocon-
verters were analyzed for HCV transmission and evolution for a
period of 1–2 years. Five (subjects, A, B, C, E and F) of the six
subjects were HIV positive for 3–10 years before HCV infection,
and one (subject D) was infected with both HIV and HCV within a
window of 6 months. At the time of HCV infection, 5/6 subjects
were naïve to HAART, except subject B who was treated with
HAART. All six subjects were naïve to anti-HCV treatment. The
median plasma HCV load of the six subjects at the ﬁrst HCV RNA
positive visits was 5.2106 copies/ml (ranging from 2.9104 to
3.3107), and the median plasma HIV load of ﬁve subjects at the
same visits was 1.6105 copies/ml (ranging from 1.8103 to
6.5105 copies/ml), while plasma HIV load was undetectable in
one subject due to antiretroviral treatment (Table 1).
The sequences corresponding to HCV envelope E1/E2 region
(corresponding to HCV H77 nt: 843–1868, 1026 bp) from the ﬁrst
HCV RNA positive samples of all six patients were subjected to
neighbor-jointing (NJ) phylogenetic analysis. To evaluate the
number of the transmitted infectious founder viruses for HCV
infection, the Poisson Fitter statistical model (http://www.hiv.lanl.
gov/content/sequence/HIV/HIVTools.html) was used to examine
whether the viral population had a star-like phylogeny with a
Poisson distribution. Both the Poisson Fitter test and phylogenetic
analyses indicated that four subjects (C–F) were initially infected
by a single HCV variant (Fig. 1A for subject E), while subject A and
subject B were infected by three closely related founder viruses
(Fig. 1B for subject B). Figures for subjects F, C, D and A are
included in the supplement Fig. 1A–D. The highlighter plots of the
sequences from these four subjects with a single founder virus
showed that the mutated nucleotides were randomly distributed,
and the phylogenetic tree showed only one cluster consistent with
a star-like distribution of variants arising from a single founder,
which is supported by Poisson Fitter analysis. The sequence
maximum median distances were 0.25% (0.20–0.73%) in four
subjects (subjects E, F, C, and D) with one founder virus and
1.32% (1.01–1.62%) for subjects A and B with three founder viruses
(Table 1). These results indicate that limited number of viral
variants initiated the clinical infection and there was a genetic
bottleneck in HCV transmission in all subjects despite of a wide
spectrum of CD4 cell count when HCV infection started.
HCV evolution over the course of infection
A total of 455 E1/E2 gene sequences, approximately 1000 bp
long with a median of 20 sequences per sample (range 17–32),
were used for evolutionary analysis. Phylogenetic analysis of
longitudinal HCV sequences of ﬁve patients is shown in Fig. 2.
Sequences from each individual subject formed subject-speciﬁc
clusters with no intermixing of sequences among subjects. These
ﬁve subjects were infected with HCV subtype 1a based on the
blasting results of the viral sequences with NCBI nucleotide data
base. The other subject (subject B) was initially infected with HCV
subtype 3a (Fig. 3A), and then one year later was re-infected with
HCV subtype 1a (Fig. 3B). Therefore, all subsequent longitudinal
sequence analysis for subject B was based on the sequential
sequences of HCV subtype 1a following infection with subtype 1a.
In general, viral quasispecies sequences at the time of infection
were more homogeneous compared to those at later time points.
During 1–2 years of follow-up with 3 sequential visits for each
patient, there was a temporal evolutionary trend with a shift of
viral quasispecies in four of six subjects from one visit to next visit,
regardless of whether the HCV infection started with low (subject
A and subject C with CD4 cell count 274 and 13, respectively) or
high CD4 (subject D and subject F with CD4 cell count 807 and 497,
respectively) cell count (Fig. 2). In the other two subjects (subjects
E with CD4 cell count 559 cells/mm3 and subject B with CD4 cell
count 171 cells/mm3), the viral quasispecies at later time points
intermingled with the sequences from previous time point (Figs. 2,
and 3A). As described previously, subject B was on antiretroviral
therapy with presumably improved immune system when HCV
infection occurred. However, the HCV evolutionary pattern in
subject B was similar to that of HCV from subject E. The dynamics
of viral diversity and divergence of HCV quasispecies during the
follow up period were also examined in six patients. Viral diversity
was increased as the virus infection transitioned from acute to
chronic phase during subsequent 1–2 years of infection. Regres-
sion analysis showed that there was a strong association between
Table 1
Clinical and laboratory information of the six patients coinfected with HCV/HIV.
Sample Age length of HIV
infection (years)
CD4
(cells/mm3)
HIV load
(cp/ml)
Time of HCV
infection
(years)
HCV load
(*103 cp/ml)
Star-like
phylogeny
Maximum
distance
ALT/AST
A-V1 42 8 274 647,299 0.83 2,350 Yes 1.01% NA
A-V2 316 1,088 NA NA
A-V3 451 7,934 4177 NA
B-V1 45 10 171 o40 0.25 33,021 No 1.62% NA
B-V2 272 o40 603 33/33
B-V3 491 o40 2,165 27/26
B-V4 333 o40 NA 24/24
C-V1 37 7 13 NA 0.47 8,059 Yes 0.73% NA
C-V2 8 630,703 15,510 32/50
C-V3 18 111,854 10,208 45/49
D-V1 41 0.5 807 1,806 0.23 29 Yes 0.2% NA
D-V2 605 27,954 350 NA
D-V3 585 119,962 687 NA
E-V1 43 3 559 294,000 0.50 12,492 Yes 0.73% 101/74
E-V2 291 687,000 10,061 55/85
E-V3 527 73,700 6,401 146/116
F-V1 36 9 497 20,836 0.24 1,510 Yes 0.23% NA
F-V2 452 NA 3,436 NA
F-V3 677 NA 4,886 NA
NA, not available.
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the infection time and overall viral diversity (P¼0.0024, R2¼44.6%)
(Fig 4A), indicating that the viral mutation and evolution were
associated with the length of viral infection. In addition, the viral
divergence from initial time point also showed the similar pattern
(Fig. 4B), with the increasing of infection time, the viral divergence
increased (P¼0.00149, R2¼46.3%). Moreover, there was no associa-
tion between CD4 cell count at the onset of HCV infection and viral
diversity and divergence after 1.0–2.0 years of HCV infection (Fig. 4C).
Fig. 1. Neighbor-joining (NJ) trees and highlighter plots of HCV E1/E2 sequences from ﬁrst time point after HCV infection. E1/E2 sequences are depicted by NJ tree
phylogenies (left) and highlighter plots (right). Panel A: Sequences from subject E (CD4 cell count 559 cells/mm3) infected by a single founder virus; Panel B: Sequences from
subject B (CD4 cell count 171 cells/mm3) infected by three closely related viruses that are distinguished by a set of several nucleotide polymorphisms.
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Immune pressure and selection of mutation
Viral random mutations arise from the lack of proofreading
polymerase. However, the proﬁles of the mutation dynamics are
shaped by viral ﬁtness and immune selection. To evaluate immune
selection of viral sequences in the six co-infected subjects, the
non-synonymous (dN) to synonymous (dS) substitutions in sliding
windows across E1/E2 envelope region were monitored as HCV
infection proceeded from acute to chronic stages during the 2 years
of follow up after infection. Sliding window analysis (Fig. 5)
demonstrates an increase of synonymous over non-synonymous
substitutions throughout the envelope regions in all six subjects.
The median synonymous distance was greater than that of the
non-synonymous distance from the ﬁrst time point to the second
time point (0.5 year apart, 0.1328 versus 0.0196, Po0.001).
Similarly, the synonymous distance from the ﬁrst time point to
the third time point (1–2 years apart), was also greater than the
non-synonymous distance during that period (0.126 versus 0.021;
Po0.001). The greater synonymous distances compared to the
non-synonymous distances suggests that host purifying selection
dominated nucleotide changes during the ﬁrst 1–2 years of acute
HCV infection regardless of host CD4 cell count when the HCV
infection started.
Assessment of host cellular immune pressure on viral genome
evolution
Although the role of HCV speciﬁc immune response in control-
ling HCV replication at the initial phase of infection is still
controversial, a strong cellular immune response is often detected
in acute stages of HCV infection (Cooper et al., 1999; Gruner et al.,
2000; Lechner et al., 2000; Takaki et al., 2000; Thimme et al.,
2001). To evaluate viral genome mutations with the evasion of
host T cell immunity against HCV in HIV-infected subjects with
different CD4 cell count background, the predicted T cell epitopes
in the E1/E2 region based on the binding afﬁnity between the
Fig. 2. Phylogenetic trees of HCV E1/E2 sequences of ﬁve studied subjects. The center neighbor-joining tree demonstrates the phylogenetic relationship among the
sequences from different subjects. All sequences are represented by colored circles. For each study subject, a neighbor-joining tree was constructed based on the sequences
from 3 visits with 17–32 sequences per visit. The black, green and red circles indicate sequences ampliﬁed from ﬁrst visit, second visit and third visit, respectively. Asterisks
on branches indicate bootstrap values greater than 99%.
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amino acid sequences and respective host HLA class I and class II
alleles (obtained from MACS data center) were analyzed in 5 of
6 subjects (HLA alleles of subject E were not available).
For HLA class I restricted epitopes, the regions with predicted
binding afﬁnity o50 nM were deﬁned as strong binding epitopes,
and the regions with the binding afﬁnity between 50 and 500 nM
Fig. 3. Neighbor-joining tree of HCV E1/E2 sequences from patient B. Panel A: The tree was constructed based on the sequences from four consecutive visits of subject B. The
ﬁrst time point sequences (black empty square) clustered differently from the rest three follow-up visits by a high bootstrap support value (99%). The black, green and red
circles indicate sequences ampliﬁed from three different visits. Panel B: The tree was constructed using viral sequences from subject B and HCV subtype 1 and 3 reference
strains obtained from the Los Alamos HCV database. For clarity the patient sequence clusters with high bootstrap value were collapsed. There are two clusters, one is HCV
subtype 1a and the other is HCV subtype 3a.
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were deﬁned as weak binding epitopes (Lundegaard et al., 2008a,
2008b). For each subject, the predicted HLA class I restricted
epitopes at the ﬁrst time point were compared with those at
subsequent visits. In subjects D and patient F with CD4 cell count
807 and 497 cells/mm3, 5–6 HLA class I restricted strong binding
epitopes and 12–17 weak binding epitopes were detected. In
subject A, subject B and subject C, with CD4 cell count of 274,
171 and 13 cells/mm3, respectively, three class I strong binding
epitopes and 11–20 weak binding epitopes were detected. The
epitope changes from a representative subject D and subject A are
shown in Fig. 6. The epitope changes in rest of the subjects are
summarized in supplemental Fig. 2. As infection proceeded, none
of the class I strong binding epitopes changed at subsequent time
points. Only one weak binding epitope in subject A (CD4 cell count
274 cells/mm3) lost its predicted binding afﬁnity to HLA allele and
one strong binding epitope changed to weak binding one at
subsequent time points (Fig. 6B). These results suggest that there
were no signiﬁcant changes in the strong or weak binding
epitopes during the initial 1–2 years of HCV infection in the ﬁve
subjects with CD4 cell count ranging from 18–807 cell/mm3 at the
time of HCV infection.
For HLA Class II epitopes, the regions with predicted binding
o500 nM were deﬁned as potential binding epitopes (Wang et al.,
2010). Similarly, in each subject, the epitopes predicted on the
viral amino acid sequences from the ﬁrst time point were
monitored at the subsequent visits. In subject D and subject F
(CD4 cell count 807 and 497) 20–46 epitopes were detected. In
subject A, subject B, subject C (CD4 cell count 274, 171 and 13) 25–
50 epitopes were detected. However, no signiﬁcant changes of the
epitopes were detected in any of the ﬁve subjects as HCV infection
progressed from acute to chronic phase. The list of predicted HLA
class I and II restricted epitopes in E1/E2 region and corresponding
mutations were shown in Supplemental Tables 1 and 2. It is
possible that the immune pressure on the epitope regions was
different comparing to the epitope-ﬂanking regions. Therefore, we
evaluated the ratio of non-synonymous versus synonymous muta-
tions in the predicted epitope regions as well as the epitope-
ﬂanking regions as shown in Table 2. For all ﬁve patients, the ratios
derived from these two regions were less than 1 suggesting no
signiﬁcant difference in immune selections on these two regions.
Evaluation of neutralizing antibody epitopes in hypervariable
region 1
Hypervariable region 1 (HVR1) located at the beginning part of
HCV E2 region is composed of 27 amino acids that include
neutralizing antibody epitopes. Mutations in HVR1 are often
associated with escape from neutralizing antibodies produced
Fig. 4. Relationship between viral diversity, divergence and length of HCV infection. Scatter plot shows relationship between length of HCV infection and the viral diversity
(Panel A) or Viral divergence (Panel B). There is a strong association between the length of viral infection and viral diversity or divergence in all six patients, P¼0.0024 and
P¼0.0149 respectively. Panel C shows the association between the viral diversity (black solid circles and black solid line), divergence (black empty circles and black dash line)
at the time of 1.0–2.0 years of HCV infection and the CD4 cell count at the time of HCV infection. r¼0.3 for divergence and r¼0.3 for diversity, p40.05 for both analysis.
HVR1
D
is
ta
nc
e 
(N
ei
-G
oj
ob
or
)
Fig. 5. The no-nsynonymous and synonymous nucleotide changes from ﬁrst visit
vs second visit and ﬁrst visit vs third visit by sliding window Analysis. An average
non-synonymous and synonymous distance for all pairwise comparisons was
calculated with a 20-nucleotide sliding window and 1-nucleotide step. Average
synonymous change from ﬁrst visit vs second visit is indicated by a green line and
synonymous change from ﬁrst visit vs third visit by a purple line. Non-synonymous
change from ﬁrst visit vs second visit is indicated by a dark blue line and non-
synonymous change from ﬁrst visit vs third visit by a red line. HVR1 is depicted at
the top by a red bar.
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during acute HCV infection (Dowd et al., 2009; Guan et al., 2012).
Examination of HVR1 regions in 6 subjects during ﬁrst
1–2 years of HCV infection showed that there were no amino
acid changes in ﬁve subjects during this period. However, a few
amino acid changes were detected in subject A (CD4 cell count 274
cells/mm3) as the virus evolved from acute to chronic stages
(Fig. 7). For subject A, 90% of proline at position 2 and 80% of
arginine at position 21 at initial infection were changed to threonine
within 6 months of infection. Additionally, after 2 years of infection,
70% of phenylalanine residues at position 16 were changed to leucine
and 10% changed to isoleucine. The amino acid changes in remaining
ﬁve subjects are not signiﬁcant and summarized in the supplemental
Fig. 3. These results indicate that there was limited immune pressure
in HVR1 evolution during initial 1–2 years of infection regardless of
the host CD4 cell count at the onset of HCV infection.
HIV and HCV co-evolution in a dually infected subject
In ﬁve of six HIV/HCV co-infected subjects in our study, HCV
infection started in the hosts with pre-compromised immune
system due to 3–10 years of HIV infection. However, we had
accessed to one subject (subject D) who was infected with HCV
within six months of HIV infection, which provided us an oppor-
tunity to evaluate HIV and HCV co-evolution from acute to chronic
infection under the same presumably uncompromised immune
system. As shown in Fig. 8, sequences encompassing envelope
C2-V5 region of HIV (Fig. 8, left in panel A) and E1/E2 region of
HCV (Fig. 8, left in panel B) at the ﬁrst time point were quite
homogeneous (sequences shown in blue dots in phylogenetic
trees) indicating transmission bottleneck in both viruses. As the
infection proceeded from acute to chronic phase, the diversity
increased for both viruses, but the diversity of HIV (Fig. 8, middle
in panel A) increased much faster than that of HCV (Fig. 8, middle
in panel B). The HIV diversity observed here is compatible with
HIV diversity reported in our previous study (Shankarappa et al.,
1999). After one and half year of the co-infection, overall diversity
of HIV was 2 times higher than that of HCV. In addition, there were
more apparent amino acid changes in HIV than those of HCV
(Fig. 8, right in panel A and B). Although viral mutations were
controlled by respective rate of viral replication, characteristics of
error-prone polymerases and virus ﬁtness, our data suggest that
the host may control these two viruses by different mechanisms.
Fig. 6. The dynamic changes of the predicted HLA class I restricted epitopes on E1/E2 region. The changes of HLA class I restricted epitopes at amino acid level from subject D
(Panel A) and subject A (Panel B) are shown. Gray boxes indicate the predicted weak binding epitopes, Black boxes indicate the predicted strong binding epitopes.
Table 2
The ratio of non-synonymous verse synonymous substitutions in HLA class I
restricted epitopes and the epitope-ﬂanking regions.
Patient ID dN/dS (epitope regions) dN/dS (epitope ﬂanking regions)
A 0.464 0.402
B 0.140 0.295
C 0.233 0.056
D 0.169 0.304
F 0.450 0.229
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Proinﬂammatory cytokine proﬁles in the plasma samples
Host immune system plays an important role in pathogenesis of
HIV/HCV infection (Flynn et al., 2013; Nishitsuji et al., 2013). Inﬂam-
matory cytokines are thought to be directly involved in the immune
responses against HIV/HCV replication. Therefore, levels of seven
proinﬂammatory cytokines (INFγ, IL-10, IL-12p70, IL-1β, IL-6, IL-8
and TNF-α) were measured in the plasma samples from the six
HCV-infected subjects at the ﬁrst visit after HCV infection and
subsequent visits. In most of the subjects, regardless of their CD4
numbers, low levels (less than 30 pg/ml) of plasma inﬂammatory
cytokines were detected at all visits (data not shown). We also
evaluated the levels of ALT/AST in plasma which could be useful
indicators of liver inﬂammation and potentially an immune response
against liver. Of the 6 patients, the AST/ALT data are available from
3 patients (2 patients with infection initiated with low CD4 counts and
1 with infection initiated with high CD4 count) (Table 1). All AST/ALT
are below 150 IU/L. These preliminary data suggest that liver inﬂam-
mation in these patients was mild.
Discussion
HCV evolution has been studied in detail in HCV-infected
subjects. However, global rapid rise of acute HCV infection in
HIV-infected subjects through sexual and intravenous drug abuse
requires a detailed investigation of HCV evolution and the role of
immunity in viral evolution in HIV/HCV co-infected subjects. The
availability of plasma samples with deﬁned onset of HCV infection
and longitudinal follow up in highly characterized HIV-infected
subjects from the Multicenter AIDS Cohort Study (MACS) provided
us a unique opportunity for the ﬁrst time to study HCV evolution
from the onset of HCV infection under different pre-existing
immune environment manifested by prior HIV infection.
In this study we measured HCV evolution in 6 HIV-infected
subjects with a wide spectrum of CD4 cell counts at the onset of
HCV infection. Analysis of 455 independent HCV E1/E2 sequences
from initial infection up to 1–2 years after infection revealed that
HCV infection in all six subjects was initiated with only 1 or
3 founder viruses, indicating that there was a signiﬁcant
transmission bottleneck in HCV transmission at all subjects. Long-
itudinal analysis of HCV sequences over a period of 1–2 years
showed two modes of viral evolution as the infection progressed
from acute to chronic phase. In 4/6 subjects there was a replace-
ment of viral quasispecies from one visit with those from sub-
sequent visits, while in 2/6 subjects viral quasispecies from later
time points intermingled with those of earlier time points. How-
ever, such viral evolution was independent of host CD4 cell count
at the time of HCV infection. In addition, both diversity and
divergence from initial viral population at the time of infection
increased with time and were very similar in all subjects regard-
less of their CD4 cell count at the time of HCV infection. These
results suggest that preexisting CD4 levels in the host may not
have effect on HCV evolution and hence replication.
Viral sequences were then used to compare evolutionary
pressure in subjects with different CD4 cell count by measuring
non-synonymous (dN) to synonymous (dS) substitution across
E1/E2 region during 1–2 years as the infection proceeded from
acute to chronic phase. Pairwise synonymous distance within this
period of time was greater than non-synonymous distance, indi-
cating that purifying selection was the major force modulating
viral population at the beginning of the chronic phase of infection.
We then monitored the dynamic changes of predicted HLA class I
and II restricted T cell epitopes in the HCV envelope region as a
measure of CD8 and CD4 T cell mediated immune pressure on viral
evolution. Except one change in the weak binding epitope for HLA
class I, there were no signiﬁcant changes in HLA class I and II binding
epitopes in subsequent visits in all ﬁve subjects, which indicates there
are limited immune pressure against HCV in these HIV infected
individuals. Our results are consistent with recent studies, which
showed that HIV infection greatly compromised the host immune
system to control HCV (Flynn et al., 2012; Low et al., 2008; Rotman
and Liang, 2009; Schnuriger et al., 2009) and contrasted with the
changes of immune epitopes observed in HCV mono infected indivi-
duals (Bailey et al., 2012; Cox et al., 2005).
Since a number of studies have reported that virus neutralizing
antibody response is the driving force for viral evolution and viral
clearance (Pestka et al., 2007), we have examined virus neutraliz-
ing epitopes present in the hypervariable region 1 of the HCV
envelope gene. In most (5/6) of the subjects we did not detect any
Visit 1
Visit 2
Visit 3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Fig. 7. Dynamic amino acid changes of HVR1. Sequence logos were used to demonstrate the amino acid changes of the HVR1 from ﬁrst visit, second visit and third visit for
subject A. The size of the amino acids in the sequences logos is proportional to the percentage of amino acid quasispecies in that visit. Numbers on the top of the ﬁgure
indicate the amino acid position of HVR1 region. Black arrows show the changes of the amino acids.
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changes in neutralizing epitopes in the hypervariable region
1 within the 1–2 years of infection as it proceeded from acute to
chronic phase regardless of subjects' preexisting CD4 levels.
The cumulative results reported here have shown that trans-
mission bottleneck and evolution pattern as determined by HCV
diversity, divergence and occurrence of mutations important for
adaptive immunity are independent of CD4 cell count at the time
of HCV infection. Even in HIV-infected subjects with very low CD4
cell count, like 13 cells/mm3 (impaired immunity presumably due
to prior HIV infection) and relatively high CD4 cell count, like 807
cells/mm3 (presumably near intact immunity), HCV transmission
and evolution are very similar. These results led us to speculate
that host immunity may handle these two viruses differently. This
speculation is supported by our results in a subject who was
infected with HIV and HCV within a very short period of time.
Here we observed that viral diversity and divergence were much
higher in the case of HIV as compared to HCV in the same
immunocompetent host. In addition, in this subject there were
more frequent mutations and amino acid changes in HIV than in
HCV, suggesting that host might exert different immune pressure
against these two viruses. There are several potential caveats to
these conclusions: First: predicted immune response epitopes
must be veriﬁed by actual T cell response data with CD8 and
CD4 cells from co-infected subjects. Second: we examined T cell
immune response in envelope region. We need to examine non-
envelope region to make our conclusion more general, because
there are reports indicating signiﬁcant difference in HCV evolution
between envelope and non-envelope region (Bailey et al., 2012;
Liu et al., 2010). Third, sample size is relatively small. Further
studies are needed in both envelope and non-envelope genes with
more co-infected subjects in order to conﬁrm this speculation.
Material and methods
Study subjects
Plasma samples from six HCV seroconverters (5 RNAþ/Ab
and 1 RNAþ/Abþ) with HIV infection and CD4 cell count ranging
from 13 to 807 cells/mm3 at the time of HCV infection were
obtained from the subjects enrolled in MACS. Semiannual or
annual plasma samples starting from the earliest time of HCV
RNA positivity up to 1.0–2 years after infection were used for this
study and at least three time points were analyzed for each
subject. The estimated time of infection relative to the ﬁrst visit
sequenced was calculated as half of the days between the ﬁrst HCV
positive visit and the last negative visit, which was converted to
years. The median age of the 6 subjects was 41 years (range 37–45)
Fig. 8. HCV and HIV coevolution in HIV/HCV co-infected patient D. Panel A: Neighbor-joining tree of HIV C2-V5 sequences (left), HIV Viral diversity analysis (middle), and
highlighter plot (right). Panel B. Neighbor-joining tree of HCV E1/E2 sequences (left), HCV Viral diversity analysis (middle), and highlighter plot (right).
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when HCV infection occurred. All HCV infections were acquired by
sexual transmission. Five of the patients were initially infected
with HCV subtype 1a.
Multiplex cytokine measurement
Levels of eight inﬂammatory cytokines (IFN-g, IL-10, IL-12p70,
IL-1b, IL-6, IL-8 and TNF-a) in plasma were measured by Meso
Scale Discovery (Meso Scale Discovery, Rockville, MD) assay
following manufacture protocols.
Nucleic acid extraction, viral load measurement and single genome
ampliﬁcation
Total RNA was extracted from 200–500 μl plasma samples
using the automatic NucliSens EasyMag nucleic acid extraction
machine (bioMérieux, Durham, NC). To measure HCV load,
extracted plasma RNA were subjected to reverse transcription
(RT) followed by real time PCR using commercially available HCV
primers/probe following manufacture's instruction (Applied Bio-
systems, Foster City, CA). HIV viral load was measured by Amplicor
assay (Roche, Indianapolis, IN). For single genome ampliﬁcation
(SGA) of E1/E2 region of HCV, total RNA extracted from the plasma
was subjected to reverse transcription followed by single genome
ampliﬁcation as described previously (Salazar-Gonzalez et al.,
2008; Shen et al., 2012). Brieﬂy, each RT reaction included 1RT
buffer, 0.5 mM of each of the four deoxynucleoside triphosphates,
5 mM dithiothreitol, 2 units/μl RNaseOUT (RNase inhibitor), 10
units/μl of Superscript III reverse transcriptase, and 0.25 μM
antisense primer, 1000outerR 5′ GGGCAGDBCARRGTGTTGTTGCC,
which was also used in subsequent nested-PCR as an outer reverse
primer. The reverse transcription was carried out at 50 1C for
60 min followed by an increase in temperature to 55 1C for an
additional 60 min. The reaction was then heat-inactivated at 70 1C
for 15 min. The synthesized cDNA was then used for HCV speciﬁc
nested PCR ampliﬁcation. The primers for the ﬁrst round of the nested
PCR were: 1000outerF 5′ GCAACAGGGAACCTTCCTGGTTGCTC, 1000-
outerR 5′ GGGCAGDBCARRGTGTTGTTGCC; and the primers for the
second round of nested PCR were: 1000innerF 5′ AACCTTCC-
TGGTTGCTCTTTCTCTAT and 1000innerR 5′-GAAGCAATAYTGYGGRC-
CACA. The single genome ampliﬁcation of HIV C2-V5 region was
performed as described previously (Salazar-Gonzalez et al., 2008; Shen
et al., 2012).
Sequencing and phylogenetic analysis
Amplicons were directly sequenced in an ABI Prism 3700 DNA
Sequencer. CLC main workbench 6.0 was used to inspect the
chromatograms. The sequences without mixed bases were taken
as an evidence of single genome ampliﬁcation from a single viral
RNA template. The median number of sequences analyzed per
time point was 20 (range: 17–32). DNA alignments were con-
structed using CLUSTAL X alignment program and hand adjusted
when necessary. The sequences were visually inspected by using
neighbor-joining phylogenies implemented in MEGA5.0 to com-
pute the viral diversity, divergence and construct phylogenetic
tree. The sequence visualization tools, highlighter (www.HIV.lanl.
gov) and Poisson Fitter program (www.HIV.lanl.gov) together with
phylogenetic tree were employed to predict the number of
founder viruses. Poisson Fitter program was based on the ﬁt of
the Poisson model to the frequency distribution of the Hamming
distance observed in each sample. For the transmission genetic
bottleneck analysis, only the HCV sequences obtained from the
earliest time point after HCV infection from each subject were
included in the founder virus analysis.
Analysis of the regions important to immune functions
Sliding window analysis of non-synonymous and synonymous
changes was performed with VarPlot (v1.7; http://sray.med.som.
jhmi.edu/SCRoftware/VarPlot), and ratios of dN and dS were
calculated by the Nei-Gojobori method (Nei and Gojobori, 1986).
The HLA Class I and Class II restricted epitopes in the ampliﬁed
E1/E2 regions were predicted using available algorithms in http://
www.immuneepitope.org based on individual patient's HLA types
provided by MACS data center (Gao et al., 2010). For HLA Class I
restricted epitopes, the results presented were derived from
website NetMHC http://www.cbs.dtu.dk/services/NetMHC/, which
used an artiﬁcial neural network for predictions. For HLA Class II
restricted epitopes, the prediction results were derived using the
software from website: http://tools.immuneepitope.org/analyze/
html/mhc_II_binding.html#.
Furthermore, the ratios of synonymous verse non-synonymous
mutations of the predicted epitope regions and the epitope-
ﬂanking regions were evaluated using DnaSP (5.10.1) (Librado
and Rozas, 2009).
Statistical analysis
Signiﬁcance of differences in diversity, divergence and amino
acids evolution were calculated using Mann-Whitney U Test. For
the longitudinal data, linear regression utilizing generalized esti-
mating equations (GEEs) and an exchangeable correlation struc-
ture (Zeger and Liang, 1986) models were employed to analyze the
relationship between viral divergence, diversity and duration of
viral infection. The association between viral diversity, divergence
and CD4 cell count at the onset of HCV infection were analyzed by
using spearman correlation. The data were analyzed using the
Stata version 11.0 statistical software (Stata Press, College Station,
TX, USA).
Nucleotide sequence accession numbers
Sequences were deposited in GenBank under the accession no.
KC614812–KC615266.
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